Grupo Espanol De Leucemia Mieloide Cronica

The Grupo Español de Leucemia Mieloide Crónica (GELMC) is a prominent Spanish cooperative research group focused on advancing the diagnosis and treatment of Chronic Myeloid Leukemia (CML). As a specialized branch of the Spanish Society of Hematology and Hemotherapy (SEHH), the group facilitates multicenter clinical trials and translational research across Spain. GELMC is particularly recognized for its work in optimizing tyrosine kinase inhibitor (TKI) therapy and establishing protocols for treatment-free remission (TFR). The organization also maintains a national registry of CML patients to monitor long-term outcomes and the efficacy of new therapeutic agents. By collaborating with international consortia, GELMC ensures that Spanish hematologists remain at the forefront of CML management and molecular monitoring standards.